Clinical Trial Update: BT-011 Pharmacokinetics of Botulism Antitoxin Heptavalent in Pediatric Patients [Phase 4]

View source ↗

Summary

An update on a Phase 4 pharmacokinetic study of botulism antitoxin heptavalent (BT-011) in pediatric patients, currently enrolling by invitation.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Botulism

Drugs mentioned

• Botulism antitoxin heptavalent (BT-011) (botulism antitoxin heptavalent)

Snippet

Sponsor: Emergent BioSolutions | Conditions: Botulism | Phase 4 | Status: ENROLLING_BY_INVITATION